Amneal Pharmaceuticals LLC is pleased to announce that the company has won the global “Company of the Year” Award from Generics bulletin, a newsletter which provides commercial and regulatory information for the global generics and biosimilars industries. Presented on October 7 at the Global Generics & Biosimilars Awards 2014 held in Paris, France, the award recognizes Amneal’s rapid growth in North America.
Amneal is the 7th largest U.S. generics manufacturer based on prescriptions dispensed, according to IMS Health. The company’s 76 FDA-approved generic medications and robust pipeline of 264 products filed with the U.S. FDA or in development cover a broad range of therapeutic categories. In addition to high-volume commodity medicines, Amneal’s portfolio contains many high-barrier-to-entry and difficult-to-formulate products and spans almost the entire range of dosage forms in the market.
To produce the highest quality generic medications for its customers and accelerate its incredible growth, Amneal is making major investments in research and development, infrastructure, and human capital. The company will spend more than $400 million on R&D and capital improvements to its nine manufacturing plants in the U.S. and India over the next two years. Amneal has also invested considerable resources in human capital as well as product development and now employs over 2,600 worldwide.